恒瑞医药：SHR-A1811注射液获药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of SHR-A1811(sc) injection, which will commence shortly [1] Group 1: Product Development - The SHR-A1811 is designed to bind to HER2-expressing tumor cells and release toxins within the lysosomes, inducing cell cycle arrest and triggering apoptosis in tumor cells [1] - The released toxins exhibit high membrane permeability and can exert a bystander killing effect, enhancing anti-tumor efficacy [1] - SHR-A1811(sc) is a subcutaneous formulation developed based on the injectable SHR-A1811, expected to shorten clinical administration time and improve convenience of administration [1]